Abstract:Despite a generally better prognosis than high-grade glioma (HGG), recurrence and malignant progression are the main causes for the poor prognosis and difficulties in the treatment of low-grade glioma (LGG). It is of great importance to learn about the risk factors and underlying mechanisms of LGG recurrence and progression. In this study, the transcriptome characteristics of four groups, namely, normal brain tissue and recurrent LGG (rLGG), normal brain tissue and secondary glioblastoma (sGBM), primary LGG (pLGG) and rLGG, and pLGG and sGBM, were compared using Chinese Glioma Genome Atlas (CGGA) and Genotype-Tissue Expression Project (GTEx) databases. In this study, 296 downregulated and 396 upregulated differentially expressed genes (DEGs) with high consensus were screened out. Univariate Cox regression analysis of data from The Cancer Genome Atlas (TCGA) yielded 86 prognostically relevant DEGs; a prognostic prediction model based on five key genes (HOXA1, KIF18A, FAM133A, HGF, and MN1) was established using the least absolute shrinkage and selection operator (LASSO) regression dimensionality reduction and multivariate Cox regression analysis. LGG was divided into high- and low-risk groups using this prediction model. Gene Set Enrichment Analysis (GSEA) revealed that signaling pathway differences in the high- and low-risk groups were mainly seen in tumor immune regulation and DNA damage-related cell cycle checkpoints. Furthermore, the infiltration of immune cells in the high- and low-risk groups was analyzed, which indicated a stronger infiltration of immune cells in the high-risk group than that in the low-risk group, suggesting that an immune microenvironment more conducive to tumor growth emerged due to the interaction between tumor and immune cells. The tumor mutational burden and tumor methylation burden in the high- and low-risk groups were also analyzed, which indicated higher gene mutation burden and lower DNA methylation level in the high-risk group, suggesting that with the accumulation of genomic mutations and epigenetic changes, tumor cells continued to evolve and led to the progression of LGG to HGG. Finally, the value of potential therapeutic targets for the five key genes was analyzed, and findings demonstrated that KIF18A was the gene most likely to be a potential therapeutic target. In conclusion, the prediction model based on these five key genes can better identify the high- and low-risk groups of LGG and lay a solid foundation for evaluating the risk of LGG recurrence and malignant progression.

Systematic Evaluation of Paired Primary and Recurrent Gliomas Identifies Key Genetic Markers for Survival and Therapeutic Targets

Comprehensive Analysis of Multi-Omics Data of Recurrent Gliomas Identifies a Recurrence-Related Signature As a Novel Prognostic Marker.

Comparison of Immune Checkpoint Molecules PD-1 and PD-L1 in Paired Primary and Recurrent Glioma: Increasing Trend When Recurrence

Molecular Pathological Markers Correlated With the Recurrence Patterns of Glioma

Integrative Genomic and Transcriptomic Analysis of Primary Malignant Gliomas Revealed Different Patterns Between Grades and Somatic Mutations Related to Glioblastoma Prognosis

Genomic profiling identified novel prognostic biomarker in Chinsese glioma patients.

Prognostic Evaluations of Recurrent Gliomas and Preliminary Efficacies of Combined Modality Therapy

Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics

Integrative analysis of transcriptome and proteome profiles in primary and recurrent glioblastoma

Whole Exome Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Primary Gliomas and Matched Recurrences

Identification of Key Genes Involved in the Recurrence of Glioblastoma Multiforme Using Weighted Gene Co-Expression Network Analysis and Differential Expression Analysis.

Differential genes and scoring criteria among immunogenomic clusters of lower-grade gliomas

Recursive partitioning analysis for survival stratification and early imaging prediction of molecular biomarker in glioma patients

Prognostic value of preoperative hematological markers combined with molecular pathology in patients with diffuse gliomas.

Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

PPIC, EMP3 and CHI3L1 Are Novel Prognostic Markers for High Grade Glioma

Distinct Aneuploid Evolution of Astrocytoma and Glioblastoma During Recurrence

A Prognostic Risk Model for Glioma Patients by Systematic Evaluation of Genomic Variations.

A multivariate retrospective analysis of high-grade gliomas: Survival and prognostic factors

Comprehensive analysis of microglia gene and subpathway signatures for glioma prognosis and drug screening: linking microglia to glioma